[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 427
Citations 0
Clinical Trials Update
February 23, 2016

Antiplatelet Drug Doesn’t Reduce Pain of Sickle Cell Anemia

JAMA. 2016;315(8):742. doi:10.1001/jama.2016.1081

Children and adolescents with sickle cell anemia who received the adenosine diphosphate–directed antiplatelet agent prasugrel had no significant reduction in painful vasoocclusive crises compared with those who received placebo, found a trial conducted in 13 countries (Heeney MM et al. N Engl J Med. doi:10.1056/NEJMoa1512021 [published online December 8, 2015]). Previous studies had suggested that prasugrel reduced markers of platelet activation and, consequently, the rate and intensity of vasoocclusive pain in sickle cell anemia.

First Page Preview View Large
First page PDF preview
First page PDF preview
×